Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its injection products also comprise Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector II needle-free auto injectors to administer human growth hormone for patients with growth retardation; and VIBEX disposable pressure-assisted auto injectors. In addition, the company develops XYOSTED for the treatment of testosterone deficiency in adult males; VIBEX auto injectors for treating anaphylaxis; and disposable pen injectors for diabetes and osteoporosis. It has strategic alliances with Teva Pharmaceutical Industries, Ltd. and AMAG Pharmaceuticals, Inc., as well as a development agreement with Pfizer Inc. The company was founded in 1978 and is headquartered in Ewing, New Jersey.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Phone609-359-3020
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$54.51 million
Profitability
Miscellaneous
Employees111
Next Earnings Date3/12/2019 (Estimated)
OptionableOptionable
Antares Pharma (NASDAQ:ATRS) Frequently Asked Questions
What is Antares Pharma's stock symbol?
Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."
How were Antares Pharma's earnings last quarter?
Antares Pharma Inc (NASDAQ:ATRS) posted its quarterly earnings results on Tuesday, August, 7th. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of ($0.02) by $0.01. The specialty pharmaceutical company had revenue of $14.16 million for the quarter, compared to analyst estimates of $13.70 million. Antares Pharma had a negative net margin of 27.84% and a negative return on equity of 59.08%. View Antares Pharma's Earnings History.
When is Antares Pharma's next earnings date?
What guidance has Antares Pharma issued on next quarter's earnings?
Antares Pharma updated its FY 2018 earnings guidance on Monday, January, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $62.5-65 million, compared to the consensus revenue estimate of $62.53 million.
What price target have analysts set for ATRS?
4 equities research analysts have issued 12-month price objectives for Antares Pharma's stock. Their forecasts range from $4.00 to $8.00. On average, they anticipate Antares Pharma's share price to reach $5.4375 in the next twelve months. This suggests a possible upside of 68.3% from the stock's current price. View Analyst Price Targets for Antares Pharma.
What is the consensus analysts' recommendation for Antares Pharma?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Antares Pharma in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Antares Pharma.
Has Antares Pharma been receiving favorable news coverage?
News coverage about ATRS stock has been trending somewhat positive on Friday, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Antares Pharma earned a coverage optimism score of 1.0 on InfoTrie's scale. They also assigned news articles about the specialty pharmaceutical company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the stock's share price in the next few days.
Who are some of Antares Pharma's key competitors?
Some companies that are related to Antares Pharma include Mazor Robotics (MZOR), Atrion (ATRI), Nevro (NVRO), Tactile Systems Technology (TCMD), AtriCure (ATRC), Orthofix Medical (OFIX), Cardiovascular Systems (CSII), K2M Group (KTWO), Luminex (LMNX), Cryolife (CRY), Intersect ENT (XENT), Cerus (CERS), AngioDynamics (ANGO), SurModics (SRDX) and OraSure Technologies (OSUR).
What other stocks do shareholders of Antares Pharma own?
Who are Antares Pharma's key executives?
Antares Pharma's management team includes the folowing people:
- Mr. Robert F. Apple, CEO, Pres & Director (Age 53)
- Mr. Fred M. Powell, Exec. VP & CFO (Age 58)
- Mr. Peter J. Graham, Exec. VP of HR, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 52)
- Mr. Keith Muckenhirn, Principal Accounting Officer, VP of Fin. & Corp. Controller (Age 56)
- Edward Kessig, VP of Sales
Who are Antares Pharma's major shareholders?
Antares Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.50%), Broadfin Capital LLC (2.19%), Sargent Investment Group LLC (1.97%), Mycio Wealth Partners LLC (1.20%), Northern Trust Corp (1.11%) and Geode Capital Management LLC (1.02%). Company insiders that own Antares Pharma stock include Fred M Powell, Jacques Gonella, Leonard S Jacob, Robert F Apple and Thomas J Garrity. View Institutional Ownership Trends for Antares Pharma.
Which institutional investors are selling Antares Pharma stock?
ATRS stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Mycio Wealth Partners LLC, Falcon Point Capital LLC, Barclays PLC, Advisor Group Inc., MetLife Investment Advisors LLC, IFP Advisors Inc and New York State Common Retirement Fund. Company insiders that have sold Antares Pharma company stock in the last year include Jacques Gonella and Robert F Apple. View Insider Buying and Selling for Antares Pharma.
Which institutional investors are buying Antares Pharma stock?
ATRS stock was bought by a variety of institutional investors in the last quarter, including Sargent Investment Group LLC, Millennium Management LLC, Fosun International Ltd, Essex Investment Management Co. LLC, Two Sigma Investments LP, BlackRock Inc., Two Sigma Advisers LP and Geode Capital Management LLC. View Insider Buying and Selling for Antares Pharma.
How do I buy shares of Antares Pharma?
Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Antares Pharma's stock price today?
One share of ATRS stock can currently be purchased for approximately $3.23.
How big of a company is Antares Pharma?
Antares Pharma has a market capitalization of $508.85 million and generates $54.51 million in revenue each year. The specialty pharmaceutical company earns $-16,740,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis. Antares Pharma employs 111 workers across the globe.
What is Antares Pharma's official website?
How can I contact Antares Pharma?
Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company can be reached via phone at 609-359-3020 or via email at [email protected]
MarketBeat Community Rating for Antares Pharma (NASDAQ ATRS)
MarketBeat's community ratings are surveys of what our community members think about Antares Pharma and other stocks. Vote "Outperform" if you believe ATRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
